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A B S T R A C T
Recent studies have shown that intradermal vaccination has great potential for T cell-mediated cancer im-
munotherapy. However, classical intradermal immunization with a hypodermic needle and syringe has several
drawbacks. Therefore, in the present study a digitally controlled hollow microneedle injection system (DC-hMN-
iSystem) with an ultra-low dead volume was developed to perform micro-injections (0.25–10 μL) into skin in an
automated manner. A synthetic long peptide derived from human papilloma virus formulated in cationic lipo-
somes, which was used as a therapeutic cancer vaccine, was administered intradermally by using the DC-hMN-
iSystem. Fused silica hollow microneedles with an inner diameter of 50 μm and a bevel length of 66 ± 26 μm
were successfully fabricated via hydroﬂuoric acid etching. Upon piercing these microneedles into the skin using
a protrusion length of 400 μm, microneedles were inserted at a depth of 350 ± 55 μm. Micro-injections of
1–10 μL had an accuracy between 97 and 113% with a relative standard deviation (RSD) of 9%, and lower
volumes (0.25 and 0.5 μL) had an accuracy of 86–103% with a RSD of 29% in ex vivo human skin. Intradermal
administration of the therapeutic cancer vaccine via micro-injections induced strong functional cytotoxic and T-
helper responses in mice, while requiring much lower volumes as compared to classical intradermal im-
munization. In conclusion, by using the newly developed DC-hMN-iSystem, very low vaccine volumes can be
precisely injected into skin in an automated manner. Thereby, this system shows potential for minimally-in-
vasive and potentially pain-free therapeutic cancer vaccination.
1. Introduction
The activation of the T-cells is necessary to elicit tumor destruction
in therapeutic cancer vaccination [1–4]. Therapeutic cancer vaccina-
tion based on tumor speciﬁc peptides holds the potential for tailor-
made immunotherapy [1,2]. The sequences of these peptides are based
on tumor antigens and contain, ideally both, a cytotoxic (CD8+) and a
helper (CD4+) T-cell epitope. The incorporation of both sequences into
a synthetic long peptide (SLP) is a proven strategy to trigger a cellular
immune response speciﬁcally directed towards the tumor. Dendritic
cells are the main key in processing and presenting antigens to T-cells to
provoke T-cell immune responses [5–7]. After in vivo administration of
an SLP vaccine dendritic cells can internalize the SLPs, and subse-
quently process and present the cytotoxic and helper T-cell epitopes
through major histocompatibility complexes (MHC) class I and class II
molecules, respectively [1,2].
Intradermal vaccination has great potential to induce potent T-cell
responses, because the skin contains large numbers of dendritic cells
[5–7]. However, the standard intradermal immunization method, per-
formed with a classical hypodermic needle and syringe (often referred
to as the Mantoux method), is known for several impracticalities [8,9].
For example, due to the shallow injection depth (< 1.2 mm [10]) and
low injection volumes (0.1 mL [10]), those injections are relatively
diﬃcult to perform and require specially trained medical personnel.
Moreover, the accuracy and precision of these injections is low, because
a vaccine formulation is often delivered too deep or leaks out of the skin
[9]. A method to overcome these hurdles is by making use of a hollow
microneedle system that is capable of accurately controlling the
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injection procedure (i.e., injection depth, injection volume, infusion
speed, etc.) [11,12]. Microneedles are needle-like structures with di-
mensions of< 1 mm that are used to overcome the skin's physical
barrier, the stratum corneum, in a minimally invasive and potentially
pain-free manner [8,11–14].
In human papilloma virus (HPV) positive cancers, the oncogenic
proteins, HPV16 E6 and E7, are targets for the T-cell repertoire. Hence,
immunodominant sequences of these proteins can be synthesized in the
form of SLPs and used as a therapeutic cancer vaccine. The adminis-
tration of a mix of such SLPs derived from the E6 and E7 protein to
patients with high-grade vulvar intraepithelial neoplasia resulted in
complete regression of premalignant lesions in 47% of the patients
[15]. Nevertheless, the SLP vaccine was not able to provoke a suﬃcient
immune response to control end-stage HPV16 positive tumors [16].
Although the preferred route of T cell vaccination is intradermal, the
mixes of 13 diﬀerent SLPs emulsiﬁed in relative large volumes of
Montanide (2.8 mL) were for practical reasons injected subcutaneously
[15,16] (a standard intradermal injection is 0.1 mL [10]). Therefore,
more eﬀective vaccine formulations may be applied in smaller volumes
via the intradermal route, which can result in further improved im-
munogenicity and eﬀectiveness of tumor vaccines.
Another promising strategy to improve the immunogenicity of
tumor antigens, and thereby improve tumor control, is to formulate
them in liposomes [3,4,17–19]. Recently, it was shown that HPV E743-
63 SLP (containing both the cytotoxic and helper T-cell epitope) for-
mulated into cationic liposomes resulted in superior immune responses
and tumor control as compared to the clinical “gold standard” vaccine
formulation (SLP emulsiﬁed in Montanide ISA-51) in mice [3]. More-
over, it was shown that changing the administration route from sub-
cutaneous to intradermal resulted in a complete regression of the tumor
(100% of the mice were tumor-free), as compared to 38% tumor-free
mice upon subcutaneous immunization [3]. Due to the improved
therapeutic eﬀect in combination with the impracticalities associated
with intradermal injections, a hollow microneedle system to deliver our
eﬀective liposomal cancer vaccine formulations in low microliter vo-
lumes in an automated manner could be beneﬁcial in therapeutic
cancer vaccination.
Therefore, in this study a cationic liposomal HPV E743–63 SLP vac-
cine [3] was combined with a newly-developed digitally controlled
hollow microneedle injection system (DC-hMN-iSystem). We show the
accuracy and precision of micro-injections and the potential of a DC-
hMN-iSystem to eﬀectively induce antigen-speciﬁc T-cells upon de-
livery of a therapeutic cancer vaccine.
2. Materials and methods
2.1. Materials
For the preparation of buﬀers and solutions, Milli-Q (MQ) water
with a resistivity of 18 MΩ cm was produced by using a Millipore water
puriﬁcation system. Polyimide-coated fused silica capillaries (375 μm
outer diameter, 50 μm inner diameter) were obtained from Polymicro,
Phoenix AZ, USA, and CapTite™ connectors were obtained from
Labsmith, USA. Ammonium hydroxide was from Brocacef BV
(Maarssen, the Netherlands) and Klinipath paraﬃn wax was purchased
from VWR (Amsterdam, the Netherlands). Sulfuric acid 95–98% (w/v),
hydroﬂuoric acid 49% (w/w), triﬂuoroacetic acid (TFA), lipopoly-
saccharide (LPS), and 96% ethanol were from Sigma-Aldrich
(Zwijndrecht, the Netherlands). Chloroform, methanol, acetonitrile,
and acetone were bought from Biosolve (Valkenswaard, the
Netherlands). Sodium ﬂuorescein was acquired from Merck Millipore
(Amsterdam, the Netherlands). 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) were purchased from Avanti Polar Lipids (Alabaster, USA) and
Vivaspin 2 membrane concentrators were acquired from Sartorius
Stedim Biotech GmbH (Göttingen, Germany). IRDye 800CW-
carboxylate was purchased from Li-cor (Lincoln, NE, USA). 10 mM
phosphate buﬀer, pH 7.4 (PB) was composed of 7.7 mM Na2HPO4
(Honeywell Fluka) and 2.3 mM NaH2PO4 (Sigma-Aldrich) in MQ water
which was sterile ﬁltrated by using a 0.22-μm Millex GP PES-ﬁlter
(Merck Millipore). Antibodies were purchased from eBiosciences
(Landsmeer, the Netherlands) and BD biosciences (Breda, the
Netherlands). Perm/Wash solution and brefeldin A were from BD
biosciences. Bovine serum albumin (BSA) was obtained from Roche
diagnostics (Almere, the Netherlands). HPV E743–63 SLP of HPV-16
protein (GQAEPDRAHYNIVTFCCKCDS), minimal HPV E749–57 peptide
(RAHYNIVTF) (He2Db), and an inﬂuenza peptide (ASNENMDAM)
(He2Db) were produced at Leiden University Medical Center (LUMC).
IL-2 (Proleukin®) was from Novartis Pharma BV (LUMC pharmacy).
Ketamine solution (10% w/v), xylazine solution (2% w/v), atropine
solution (1% w/v), ﬁcoll midotrizoate, and 1% sodium azide solution
were obtained from the LUMC pharmacy. Iscove's modiﬁed Dulbecco's
medium (IMDM) was obtained from Lonza Verniers (Verviers,
Belgium), which was supplemented with 8% (v/v) fetal calf serum
(FCS) (Greiner Bioscience (Alphen a/d Rijn, the Netherlands)), 50 μM
2-mercaptoethanol (Sigma-Aldrich), penicillin (100 IU/mL), and 2 mM
glutamine from Life Technologies (Bleiswijk, the Netherlands).
Phosphate buﬀered saline, pH 7.4 (PBS; composed of 140 mM NaCl,
8.7 mM Na2HPO4, 1.8 mM NaH2HPO4), was bought from B·Braun
(Meslungen, Germany).
2.2. Mice
Female C57BL/6 (H-2b) mice were obtained from Charles River
(L'Arbresle, France) and were maintained under standardized condi-
tions in the animal facility of LUMC. At the start of the immunization
study mice were eight weeks old. The study was carried out under the
guidelines as complied by the animal ethic committee of the
Netherlands, and was approved by the “Dierexperimentencommissie
LUMC (ADEC)” under number 1409.
2.3. Fabrication of hollow microneedles
Single hollow microneedles were fabricated from fused silica ca-
pillaries with an inner diameter of 50 μm, via a slightly diﬀerent pro-
cedure as previously described [11,12]. Fused silica capillaries were
ﬁrst cut with a diamond cutter in pieces with a length of 80 cm (inner
volume of 1.57 μL). To protect the inner lumen of the capillaries from
the etchant, paraﬃn wax was degassed for two hours in a vacuum oven
at 80 °C and was subsequently loaded into the ﬁrst 2–4 cm (40–80 nL)
of the lumen of the capillaries. After etching the capillaries into mi-
croneedles in 49% hydroﬂuoric acid for four hours, the polyimide
coating at the microneedle tips was removed by incubating the ﬁrst
2–3 mm of the etched capillaries in 98% sulfuric acid at 250 °C for one
minute. To remove the paraﬃn from the lumen, the hollow micro-
needles were placed in a water bath at 80 °C while ﬂushing them se-
quentially with 250 μL acetone and 250 μL ethanol. The fabricated
hollow microneedles were imaged with a stereo microscope (Zeiss
Stemi 2000-c) to investigate the reproducibility of fabrication (n = 8).
The dimensions of the bevel (hypotenuse and length), the inner lumen,
and the lumen diameter at the microneedle tip were determined by
using the Zen 2 software (Carl Zeiss Microscopy GmbH).
2.4. Digitally controlled hollow microneedle injection system
To accurately perform micro-injections into the skin on an auto-
mated manner, a new DC-hMN-iSystem was designed (see Fig. 1). This
system has two fewer connectors as compared to our previous system
[12], resulting in an ultra-low dead volume of 1.6 μL from the syringe
connector to the tip of the microneedle (instead of 16 μL). Furthermore,
removal of the microneedle-capillary connector on the applicator cir-
cumvents the need to ﬂush the system with 1–2 mL of formulation to
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get the system air-free prior to use.
The DC-hMN-iSystem is composed of a microneedle applicator
(Figs. 1) (1) that has a micrometer actuator to control the microneedle
protrusion length in steps of 50 μm (2). In the applicator a capillary (3),
from which one side is etched into a hollow microneedle (4), is locked
by using a CapTite™ connector (5). The non-etched side of the capillary
is connected to a 100 μL Hamilton syringe via CapTite™ connectors (6).
When the applicator's solenoid is activated, the microneedle tip (4) will
protrude through the supporting plateau (7). Furthermore, the system
contains an applicator controller unit (8) (uPRAX, the Hague, the
Netherlands) to simultaneously control the microneedle applicator and
a syringe pomp (NE-300, Pump Systems Inc.). The electronics of the
syringe pump were modiﬁed (9) to digitally control the micro-injec-
tions through the hollow microneedle via the applicator controller unit.
2.5. Digitally controlled micro-injections into skin
2.5.1. Microneedle insertion and micro-injections
To dispense a liquid drug formulation into the skin, a hollow mi-
croneedle was ﬁrst pierced into the skin via impact-insertion. The
elapsed time between the activation of the applicator's solenoid and the
moment that the microneedle protruded through the supporting plateau
(telapsed) was measured by using a microcontroller (Arduino Nano 3)
and a piezoelectric sensor (Conrad Electronics). The average velocity by
which a microneedle was pierced into the skin, was calculated by di-
viding the microneedle displacement by telapsed. The micrometer ac-
tuator was set at a protrusion length of 400 μm and the depth of mi-
croneedle insertion was determined by using ﬂuorescein-labeled ex
vivo human skin as previously described (n = 5) [11]. 150 milliseconds
after the hollow microneedle was pierced into the skin, a controlled
volume of drug formulation was injected into the skin through the bore
of the microneedle. The volume was controlled by the ﬂow rate (that
was installed on the modiﬁed syringe pump, see Section 2.4) and the
time that the syringe pump was pumping (which is controlled by the
applicator controller unit). The microneedle was retained in the skin for
30 s after pumping, after which the microneedle was automatically
retracted back into the applicator.
2.5.2. Validation of digitally controlled micro-injections
To evaluate the repeatability (precision) and accuracy of the digi-
tally controlled micro-injections, volumes of 0.25, 0.5, 1, 5, and 10 μL
of a solution of 1 mg/mL sodium ﬂuorescein in PBS were dispensed into
500 μL PBS 10 times. All volumes were dispensed at a ﬂow rate of
30 μL/min, except volumes of 0.25 μL, which were dispensed at a ﬂow
rate of 15 μL/min. The ﬂuorescence of these samples as well as the
ﬂuorescence of a range of serially diluted standard solutions, containing
0.156–20 μg/mL sodium ﬂuorescein in PBS, was measured on a Tecan
Inﬁnite M1000 plate reader (λexitation = 494 nm; λemission = 512 nm).
The accuracy of the digitally controlled micro-injections was calculated
as the relative deviation (expressed as percentage) from the corre-
sponding amount of ﬂuorescein from the calibration curve. Precision
was deﬁned as the relative standard deviation (%) of the average
amount of sodium ﬂuorescein of the repeated micro-injections
(n = 10).
2.5.3. Micro-injections into ex vivo human skin
The repeatability and accuracy of the digitally controlled micro-
injections was evaluated in full thickness abdomen ex vivo human skin
(obtained from local hospitals after informed consent from the donors
and handled according to the Declaration of Helsinki Principles). Micro-
injections of 0.25, 0.5, 1, 5, and 10 μL of a 0.1 μg/μL IRDye 800CW-
carboxylate solution in PBS were performed, whereby each volume was
injected 10 times. As a control, 15 intradermal injections with 1 μg
IRDye 800CW-carboxylate in 50 μL PBS were performed by using a
conventional 30G needle and syringe. Furthermore, for each volume
that was injected via the DC-hMN-iSystem, the corresponding amount
of IRDye 800CW-carboxylate was injected by using a 30G hypodermic
needle in a volume of 50 μL PBS as a control. The ﬂuorescence of the
skin was measured by using an IVIS® lumina II by using an ICG ex-
citation ﬁlter (wavelength of 710–760 nm) and an ICG emission ﬁlter
(wavelength of 810–875 nm) with an exposure time of 1 s. The ﬂuor-
escence data was analyzed by using Living Image® software (version
4.3.1.0.15880). The ﬂuorescence intensity (Total Radiant Eﬃciency:
([photons/s] / [μW/cm2])) of the intradermal injections (either via the
DC-hMN-iSystem or hypodermic needles) was normalized, as shown in
equation 1.
Normalized ﬂuorescence= (FluoSkin− FluoBcg)/(FluoID-1μg− FluoBcg)
* 100% (Eq. 1)
Where FluoSkin is the ﬂuorescence of micro-injected skin, FluoBcg is
the background ﬂuorescence of non-injected skin, and FluoID-1μg is the
ﬂuorescence intensity of skin injected with 1 μg IRDye 800CW-car-
boxylate in 50 μL by using a conventional 30G needle.
2.6. Preparation of HPV-peptide-containing liposomes
HPV E743–63 SLP-containing liposomes were prepared by using a
thin ﬁlm dehydration-rehydration method followed by extrusion [3,4].
First, a lipid ﬁlm was prepared in a round bottomed ﬂask from a DO-
TAP:DOPC mixture (1:1 M ratio) in chloroform by rotary evaporation.
To hydrate the lipid ﬁlm, 1 mg/mL HPV E743–63 SLP in 0.04% (w/v)
ammonium hydroxide was added to the round bottomed ﬂask until a
lipid concentration of 10 mg/mL was reached. Next, the hydrated lipid
Fig. 1. Digitally controlled hollow microneedle injection
system to perform automated micro-injections into skin at a
predetermined depth. Microneedle applicator (1); micro-
meter actuator (2); capillary (3); hollow microneedle (4);
CapTite™ connectors (5, 6); supporting plateau (7); appli-
cator controller unit (8); syringe pump (9). See main text
for explanation.
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ﬁlm was snap-frozen in liquid nitrogen and freeze-dried overnight in a
Christ alpha 1–2 freeze-dryer (Osterode, Germany). The resulting lipid
cake was rehydrated stepwise with PB to reach a lipid concentration of
10 mg/mL as follows: two times 25% of the end volume PB were added
successively to the lipid cake (with 30 min intervals) after which the
resulting 50% of PB was added (the formulation was then stabilized for
1 h). After each rehydration step the mixture was vortexed well.
The liposomes were down-sized by applying high-pressure extrusion
(Lipex extruder) through polycarbonate ﬁlters (Nucleopore Milipore,
Kent, UK) with pore sizes of 400 and 200 nm (four extrusion cycles
through each ﬁlter).
To remove non-encapsulated HPV E743–63 SLP from the liposomal
formulation, Vivaspin 2 centrifugation concentrators (molecular-
weight-cut-oﬀ: 300 kDa) were used to concentrate the liposomal for-
mulation (3–4 fold) by centrifugation at 931 G (2000 RPM) for one
hour and subsequently dilute the formulation with PB to reach the in-
itial volume. The concentration and dilution steps were performed
twice, which was followed by a ﬁnal concentration step to ca. 3–4 fold.
2.7. Characterization of the liposomal formulation
2.7.1. Dynamic light scattering
The particle size and size distribution (polydispersity index (PDI)) of
the liposomal formulation was determined by using dynamic light
scattering and the ζ-potential by using laser Doppler electrophoresis on
a Zetasizer Nano (Malvern Instruments). For these measurements 2.5 μL
of the liposomal formulation was diluted 400 fold in PB.
2.7.2. Extraction of HPV E743–63 SLP from liposomes
In order to determine the concentration of HPV E743–63 SLP in the
liposomal formulation, the SLP was ﬁrst extracted from the liposomes
by using a modiﬁed Bligh and Dyer extraction, as described below.
Three μL of the liposomal formulation was diluted in 100 μL MQ water.
Subsequently, 250 μL methanol and 125 μL chloroform were added and
the mixture was vortexed. To this mixture 250 μL 0.1 M HCl and 125 μL
chloroform were added after which it was vortexed again. Finally, the
mixture was centrifuged at 233 G (1000 RPM) for 5 min and the upper
phase was collected for quantiﬁcation of the HPV E743–63 SLP.
2.7.3. Reversed-phase UPLC analysis
For the quantiﬁcation of HPV E743–63 SLP, a UPLC system (Waters
Acquity UPLC® with a Waters C18–1.7 μm (2.1 × 50 mm) column) was
set at a ﬂow rate of 0.370 mL/min, with initially 95% solvent A (ACN
with 0.1% TFA) and 5% solvent B (MQ with 0.1% TFA), going to 79%
solvent B in 3.97 min and back to 5% solvent B after 3.99 min. Serially
diluted standards of HPV E743–63 SLP, ranging from 1.56 μg/
mL− 50 μg/mL, and HPV E743–63 SLP extracted from liposomes (5 μL/
sample) were injected into the UPLC system, after which the absor-
bance was measured for 6.00 min at a wavelength of 214 nm. Next, the
area under the curve of the standards and extracts of the HPV E743–63
SLP-containing samples, having a retention time of 2.4 min, were in-
tegrated by using MassLynx (Waters, software version 4.1).
2.8. Immunizations
Prior to each microneedle-based immunization, mice were an-
esthetized with 100 mg/kg ketamine, 10 mg/kg xylazine, and 0.2 mg/
kg atropine. The skin of anesthetized mice on the lower back at the tail
base was shaved. Mice (5 per group) were immunized twice with in-
tervals of two weeks (prime: day 1; boost: day 15) either by intradermal
injection using a 30G hypodermic needle or by using the DC-hMN-
iSystem. Mice that were immunized by using a 30G hypodermic needle
either received 30 μL PB (mock treated) or 1 nmol (2.3 μg) HPV E743–63
SLP in liposomes in a volume of 30 μL. Mice that were immunized by
using the DC-hMN-iSystem received 1 nmol HPV E743–63 SLP in lipo-
somes via a single micro-injection of 5 μL. Blood samples were obtained
from the tail vein at day 10 and at day 22. Mice were sacriﬁced at day
24 by CO2 gas after which the spleens and inguinal lymph nodes were
collected.
2.9. Analysis of antigen-speciﬁc T-cell responses by ﬂow cytometry
2.9.1. Antigen-speciﬁc CD8+ responses
The presence of E7-speciﬁc CD8+ T-cells was assessed in blood after
prime- and boost immunization, and was determined in spleens and
inguinal lymph nodes. To analyze HPV E7-speciﬁc CD8+ T-cells in
blood, red blood cells were removed by lysis prior to staining. Blood
cells, splenocytes and cells isolated from inguinal lymph nodes were
stained with ﬂuorescently-labeled (APC) MHC class I-speciﬁc tetramer
He2Db E749–57 (TM-RAHYNIVTF) for 30 min in FACS buﬀer (PBS
+ 0.1% (w/v) BSA + 0.05% (w/v) sodium azide). Next, cells were
incubated with anti CD8α-PE antibody for 20 min after which the cells
were washed twice with FACS buﬀer. Data acquisition was done with a
BD LSR II ﬂow cytometer and the data was analyzed with Flowjo
software V10 (Tree star).
2.9.2. Restimulation of splenocytes to analyze antigen-speciﬁc CD4+ and
CD8+ responses
The induction of antigen-speciﬁc CD4+ and CD8+ T-cell responses
was assessed after the mice were sacriﬁced. To this end, splenocytes
were incubated with dendritic cells (D1 cells) supplemented with HPV
E743–63 SLP. Next, the splenocytes were harvested and separated on a
ﬁcoll midotrizoate gradient (the living splenocytes were collected from
the interphase). Subsequently, the splenocytes were split over 3 wells
and were incubated with IL-2. Next, the lymphocytes were restimulated
by LPS-matured autologous dendritic cells loaded with speciﬁc HPV E7,
or control (inﬂuenza NP) or minimum (MHC class I) HPV E749–57
peptide. Finally, the cells were incubated for 5 h with brefeldin A (2 μg/
mL) and were stained for intracellular cytokines and extracellular
proteins. During the whole procedure, cells were incubated in supple-
mented IMDM in an incubator at 37 °C and 5% CO2.
2.9.3. Intracellular staining
The antigen-speciﬁc CD4+ and CD8+ T-cell responses were de-
termined by using an intracellular cytokine staining (ICS) on the res-
timulated splenocytes. Cell surfaces were stained with ﬂuorescently
labeled antibodies CD3-Pe-Cy7, CD4-Qdot605, and CD8α-Alexa Fluor®
700 in FACS buﬀer. Next, cells were ﬁxed in 1% paraformaldehyde (w/
v) for 30 min and permeabilized with Perm/Wash solution. ICS was
performed with TNFα-FITC, IFNγ-APC and IL-2-PE antibodies for
30 min at 4 °C. Finally, data was acquired by using a BD LSR II ﬂow
cytometer and analyzed in Flowjo V10.
2.10. Statistical analysis
Statistical analysis was performed by using GraphPad Prism 7 for
Windows. Data is represented as mean ± SD unless stated otherwise.
Statistical signiﬁcance of antigen-speciﬁc cytotoxic T-cells was de-
termined by using an ordinary two-way ANOVA with a Tukey's multiple
comparisons test (blood) and a one-way ANOVA with a Dunn's multiple
comparisons test (spleen and lymph nodes). The statistical signiﬁcance
of antigen-speciﬁc T-cells (restimulated splenocytes) was determined by
using a two-way repeated measurements ANOVA with a Tukey's mul-
tiple comparisons test. Statistical signiﬁcance is presented as:
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
3. Results
3.1. Characterization of the hollow microneedles
After fabricating hollow microneedles from fused silica capillaries
with an inner lumen diameter of 50 μm, the microneedle dimensions of
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each individual microneedle were measured, as shown in Fig. 2. The
inner lumen was 49 ± 3 μm (n = 8), the lumen diameter at the mi-
croneedle tip was 149 ± 26 μm (n = 8), and the hypotenuse of the
microneedle bevel was 164 ± 22 μm (n = 8). The bevel length of the
fabricated hollow microneedles was 66 ± 26 μm (n = 8) and ranged
from 24 to 97 μm.
3.2. Validation of digitally controlled micro-injections
The accuracy and repeatability of the digitally controlled micro-
injections was determined by injecting a ﬂuorescein solution into PBS.
As shown in Fig. 3A, the ﬂuorescence of the digitally controlled micro-
injections was very comparable to that of the standard solutions at the
corresponding concentration and exhibited a low relative standard
deviation (RSD = 1.68%). Fig. 3B shows that the accuracy of digitally
controlled micro-injections of 1–10 μL is between 90 and 95% with a
RSD of approximately 5%. Volumes of 0.5 and 0.25 μL had a lower
accuracy of 86% and 74%, respectively, with a higher RSD (15% and
20%, respectively).
3.3. Digitally controlled micro-injections into human skin
Single hollow microneedles were inserted into the skin by impact
insertion at an average velocity of 35 ± 1 cm/s (n=10) and a depth of
350 ± 55 μm (ranging from 257 to 392 μm). After performing micro-
injections no visible breakage or alteration of the geometry of the
hollow microneedles was observed. To reduce the chance of leakage
while performing micro-injections into skin, the applicator controller
unit was programmed in such a way that a micro-injection started 150
milliseconds after a hollow microneedle pierced into the skin.
Additionally, to reduce the chance of leakage from the site of injection,
the applicator controller unit was programmed to retain the hollow
microneedle in the skin for 30 s after a micro-injection was performed.
To determine the repeatability of the digitally controlled micro-in-
jections into skin, volumes ranging from 0.25 μL to 10 μL of a 0.1 μg/
mL IRDye 800CW carboxylate solution were injected into ex vivo
human skin via the DC-hMN-iSystem. As shown in Fig. 4, an injection of
1 μg IRDye 800CW carboxylate into ex vivo human skin in a volume of
50 μL by using a classical 30G hypodermic needle, or in a volume of
10 μL by using the DC-hMN-iSystem resulted in a similar relative
ﬂuorescence and standard deviation (100 ± 10.2% (n = 15) and
97 ± 9.8% (n = 10), respectively). Moreover, intradermal injections
of lower volumes than 50 μL using a 30G needle and syringe had a
decreased accuracy and repeatability as compared to micro-injections
of 1 μL and higher. Furthermore, the normalized ﬂuorescence of skin
injected with 25 ng – 1 μg of IRDye 800CW carboxylate via a micro-
injection of 0.25–10 μL was comparable to that of skin injected with
50 μL containing the same amount of dye by using a 30G hypodermic
needle. This data shows that the intradermally delivered (drug) dose
injected via the DC-hMN-iSystem or via a classical 30G hypodermic
needle and syringe is similarly controllable, but much lower volumes
were used in case of the micro-injections performed using the DC-hMN-
iSystem.
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3.4. Characterization of the liposomal formulation
As a therapeutic cancer vaccine HPV E743–63 SLP was formulated
into cationic liposomes. These liposomes had a hydrodynamic diameter
of 191 ± 3 nm (n = 3), a PDI of 0.22 ± 0.01 (n = 3) with a ζ-po-
tential of 26.7 ± 1.3 mV (n = 3). The HPV E743–63 SLP encapsulation
eﬃciency was 40% and the formulation contained 2.3 μg (1 nmol)
E743–63 SLP/μL liposome dispersion after the non-encapsulated peptide
was removed. For the immunization of mice, the liposomal formulation
was diluted 5-fold with PB to deliver 1 nmol E743–63 SLP in 5 μL via a
micro-injection using the DC-hMN-iSystem and 30-fold to deliver the
same amount in 30 μL PB by using a classical hypodermic needle and
syringe.
3.5. Immunization study
The potential of the DC-hMN-iSystem for minimally-invasive and
potentially pain-free vaccination was assessed in mice. As shown in
Fig. 5, mock immunization with PB did not lead to the induction of
antigen-speciﬁc cytotoxic T-cells in blood and spleen. In contrast, in-
tradermally administering HPV E743–63 SLP liposomes led to high and
comparable induction of antigen-speciﬁc cytotoxic T-cells in blood
(Fig. 5A). Immunization by performing micro-injections with the DC-
hMN-iSystem resulted in 3/5 mice having higher percentages of an-
tigen-speciﬁc cytotoxic T-cells in spleens as compared to the highest
responding mouse in the group immunized via a hypodermic needle
and syringe (Fig. 5B). Albeit micro-injections did not result in statisti-
cally signiﬁcant higher antigen-speciﬁc cytotoxic T-cells, delivery via
the DC-hMN-iSystem led to strong antigen-speciﬁc cytotoxic T-cells in
spleens which were at least similar to the ones obtained by intradermal
injections using a classical needle and syringe.
Additionally, antigen-speciﬁc T-cell responses were determined by
quantifying IFNγ+TNFα+-producing CD4+ and CD8+ (restimulated)
T-cells derived from the spleens of immunized mice. Similar to the
splenic cytotoxic T-cell responses measured ex vivo (Fig. 5), higher (but
not statistically signiﬁcant) antigen-speciﬁc (IFNγ+TNFα+) CD8+ T-
cell responses were observed when the liposomes were administered via
a micro-injection as compared to a hypodermic needle (data not
shown). As shown in Fig. 5C, restimulation with the E743–63 SLP
(containing both a cytotoxic T-cell (CD8+) sequence (RAHYNIVTF) and
a T helper (CD4+) sequence (DRAHYNIVTF) [3]), revealed that im-
munization via a micro-injection using the DC-hMN-iSystem led to
signiﬁcantly higher percentages of antigen-speciﬁc IFNγ+TNFα+-pro-
ducing CD4+ T-cells as compared to intradermal immunization by
using a conventional needle and syringe (3-fold higher). No
IFNγ+TNFα+-producing T-cells were observed when splenocytes were
restimulated with the cytotoxic T-cell sequence or control peptide, nor
when splenocytes were derived from mock immunized mice. Overall,
these data show that microneedle-based immunization leads to eﬀective
cytotoxic T-cell and helper T-cell response induction.
Fig. 4. Fluorescence imaging of ex vivo human skin into which a near infrared ﬂuorescent dye (IRDye 800CW carboxylate) was delivered by performing micro-injections (0.25–10 μL) via
the digitally controlled hollow microneedle injection system (MN) or injecting 50 μL using a classical 30G hypodermic needle and syringe (ID) (A). Normalized ﬂuorescence of MN (open
circles), and ID delivery of diﬀerent amounts of IRdye800 (closed circles) and diﬀerent volumes (triangles) (B). The accuracy and corresponding relative standard deviation (RSD) of
micro-injections (black) and ID injections (red) (n = 10) into skin (C). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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4. Discussion
In this study a new DC-hMN-iSystem was developed to accurately
and precisely deliver vaccines, in particular a liposomal therapeutic
cancer vaccine, into the skin. The new DC-hMN-iSystem was designed
to minimize the loss of formulation while performing micro-injections
in an automated manner.
Fabricating hollow microneedles from fused silica capillaries by
hydroﬂuoric acid etching is an easy, cheap and scalable method to
obtain hollow microneedles [11]. The length of the microneedle bevel
is an important parameter, since it determines the minimal length that a
hollow microneedle needs to be inserted into the skin without leakage.
The maximum bevel length of the fabricated hollow microneedles was
97 μm, which indicates that the minimum insertion depth of these
hollow microneedles to achieve a leakage-free injection is 100 μm. In a
previous study it was shown that the depth of intradermal vaccination
(ranging from 50 to 550 μm) with an inactivated polio vaccine (parti-
cles with a diameter of 30–35 nm) had no eﬀect on the immune re-
sponse in rats [12]. In this study a protrusion length of 400 μm was
chosen, because using this length results in hollow microneedles to
pierce at least 260 μm into the skin. The latter in combination with the
maximum bevel length of 100 μm should lead to leakage-free injections
and performing injections at a depth of least 160 μm.
By using the applicator controller unit, digitally controlled volumes
as low as 1 μL were shown to be accurately and precisely injected by the
DC-hMN-iSystem. The accuracy and repeatability of the micro-injec-
tions of ultra-low volumes (0.25 μL and 0.5 μL) was decreased as
compared to the higher volumes (1 μL–10 μL). This may be caused by
the stepper motor driver/controller in the syringe pump that regulates
the acceleration and deceleration that is required to start and stop the
stepper motor in a smooth way [20]. The acceleration and deceleration
may have a large inﬂuence at short pumping times, such as the 1.00 s
that was used to dispense volumes of 0.25 μL and 0.5 μL. Using a lower
ﬂow rate in combination with a longer pumping time may help to in-
crease the precision and accuracy of these ultra-low volume digitally
controlled micro-injections.
Our study shows that the (vaccine) dose that is intradermally de-
livered via micro-injections of 1–10 μL is similarly controllable as the
delivery via a classical hypodermic needle and syringe (in 50 μL).
However, the DC-hMN-iSystem has the advantage that very low vo-
lumes can be injected into the skin at low infusion rates, resulting in less
pain during administration as compared to intradermal injections via a
classical hypodermic needle and syringe [8]. Furthermore, the depth of
micro-injections is more controlled [11,12] as compared to intradermal
injections via a classical hypodermic needle and syringe. Besides, in
previous studies no visual disruption of skin was observed when micro-
injections were performed using similar injection depths, volumes and
infusion rates [11,12].
Recently, it was shown that HPV E743–63 SLP formulated into ca-
tionic liposomes were able to induce high cellular (CD4 and CD8) im-
mune responses at doses as low as 1 nmol (2.3 μg). In contrast, a 65 fold
higher dose of the SLP (150 μg) emulsiﬁed in Montanide ISA-51 was
required to obtain a similar delay on the tumor outgrowth in mice using
the same administration route (subcutaneous at the tail-base).
Moreover, it was shown that changing the administration route from
subcutaneous to intradermal resulted in a superior tumor control [3].
Such low vaccine doses open possibilities to deliver SLP-based ther-
apeutic cancer vaccine via microneedles.
Although relatively little is known about the intradermal adminis-
tration of liposomal vaccines via microneedles, a few studies have
shown that the delivery of liposomal and other nanoparticulate vac-
cines by means of microneedles can result in an eﬃcient induction of
PB ID MN
0
2
4
6
8
Blood
Tm
+
o
fC
D
8+
(%
)
Prime Boost
***
***
PB ID MN
0
1
2
3
4
5
5
10
15
Spleen
**
PB ID MN
0.0
0.5
1.0
1.5
IF
N
+
TN
F+
o
f
CD
3+
CD
4+
( %
) Control pept.MHC I pept.
MHC I+II pept.
****
**
A B
C
Fig. 5. Ex vivo HPV E7-speciﬁc CD8+ T-cell responses in
blood (after prime (day 10) and boost (day 22) im-
munization) (A) and in spleens (day 24) (B) and, HPV E7-
speciﬁc CD4+ T cell responses in spleens (C). Mice were
intradermally injected with 30 μL phosphate buﬀer (PB),
or with 1 nmol HPV E743–63 SLP in liposomes (in 30 μL PB)
via a 30G hypodermic needle (ID) or with the same dose
(in 5 μL PB) by using the digitally controlled hollow mi-
croneedle injection system (MN). RAHYNIVTF-speciﬁc
CD8+ T-cells were detected by using ﬂow cytometry and
using E7-speciﬁc MHC class I tetramers (Tm+). Antigen-
speciﬁc CD3+CD4+ T-cells responses were determined
upon restimulating splenocytes with a control peptide, a
MHC-I binding minimal peptide sequence and with a
synthetic long peptide (SLP) harboring a cytotoxic and T-
helper sequence. Interferon-γ (IFN) and tumor necrosis
factor-α (TNF) positive restimulated CD3+CD4+ spleno-
cytes are shown. Data is represented as mean + SEM,
n = 5.
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immune responses [21–29]. In these studies the liposomal vaccine was
delivered by using dissolving microneedles (hepatitis B surface antigen
(HBsAg) [21] and ovalbumin [22]), liposome-coated microneedles
(ovalbumin [25]), and skin pretreatment via microneedles (HBsAg
[23], ovalbumin [26,27], and diphtheria toxoid [28]). Besides, very
recently a study was published wherein diﬀerent protein-containing
nanoparticles, including liposomes, were administrated by using hollow
microneedles [29]. However, to our knowledge this is the ﬁrst study
reporting the microneedle-mediated delivery of a peptide-based lipo-
somal therapeutic cancer vaccine.
In this study, a cancer-speciﬁc peptide was formulated in cationic
liposomes with characteristics very similar to those of the previously
described ones [3]. Upon intradermal administration of the liposomal
formulation via micro-injections, high antigen-speciﬁc T-cell responses
were induced in blood and spleen, which were in some cases higher
than the responses obtained by using a classical hypodermic needle and
syringe. This may be the result of more superﬁcial delivery by micro-
injections or having locally higher vaccine concentrations as compared
to the injections performed by using a classical hypodermic needle and
syringe.
Summarizing, our studies demonstrate that automated intradermal
micro-injections can be easily performed with the newly developed DC-
hMN-iSystem. Besides an accurate and precise dosing, the depth of
vaccine delivery is controlled. Moreover, by using the DC-hMN-iSystem
to inject very low volumes of a liposomal therapeutic cancer vaccine
leads to strong functional T-cell (both CD4 and CD8) responses in mice.
Therefore, this study shows the potential of a DC-hMN-iSystem for
minimally invasive and potentially pain-free induction of cytotoxic and
helper T-cells for therapeutic cancer vaccination.
5. Conclusion
In this study we presented a newly developed DC-hMN-iSystem to
accurately and precisely perform micro-injections through a hollow
microneedle into the skin in an automated manner. This system was
designed to minimize the loss of expensive formulations, such as vac-
cines, by designing the ﬂuidics to have an ultra-low dead volume, and
preventing leakage by delaying the micro-injection after microneedle
insertion and retaining the microneedle in the skin after a micro-in-
jection has been performed. Moreover, using this system to in-
tradermally deliver a liposomal HPV tumor vaccine led to strong
functional cytotoxic and helper T-cell responses in mice, but in much
lower volumes as compared to intradermal vaccination using a classical
needle and syringe. In conclusion, this study shows the potential of a
DC-hMN-iSystem for easy-to-perform, minimally-invasive and poten-
tially pain-free cancer vaccination.
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